5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report

Journal of Medical Case Reports

Takanori Teshima²  Souichi Shiratori¹  Shinichi Ito¹  Hiroyuki Ohigashi¹  Yutaka Tsutsumi¹ 

[1] Department of Hematology, Hakodate Municipal Hospital, 1-10-1, Minato-cho, Hakodate 041-8680, Japan;Department of Hematology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan

关键词: Myelodysplastic syndrome;    Follicular lymphoma;    CD20;    5-Azacytidine;   

Others  :  1235812
DOI  :  10.1186/s13256-016-0809-7

 received in 2015-04-21, accepted in 2016-01-14,  发布年份 2016

【 摘 要 】

Background

The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia. Here we report a similar upregulation in a patient with follicular lymphoma who was treated with 5-azacitidine against secondary myelodysplastic syndrome.

Case presentation

A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse. After treatment of 5-azacytidine for her myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood. We also observed follicular lymphoma cell stimulation in her peripheral blood due to 5-azacytidine.

Conclusions

Although partial, CD20 expression was upregulated after treatment with 5-azacitidine. However, CD20 expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of lymphoma cell stimulation due to 5-azacitidine.

【 授权许可】

   
2016 Tsutsumi et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al.: Down-regulation of CD20 expression in B cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009, 113:4885-489.
• [2]Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, et al.: Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol. 2013, 37:563-70.
• [3]Rahmé R, Benayoun E, Pautas C, Cordonnier C, Wagner-Ballon O, Maury S: Treatment with 5-azacitidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Exp Hematol. 2013, 41:505-7.
• [4]Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, et al.: Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not DNA methylation. Biochem Biophys Res Commun. 2009, 390:48-53.